Studying mogamulizumab rash in mycosis fungoides or sezary syndrome
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at a common skin rash caused by the drug mogamulizumab in patients with certain types of lymphoma. It aims to learn more about the rash and how to manage it, so your experience can help future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mycosis fungoides or Sezary syndrome that has come back or not responded to treatment.
- Your doctor has decided to start you on mogamulizumab alone (no other lymphoma treatments, except steroid creams).
- You are willing to have a skin biopsy before and possibly during treatment if a rash appears.
- You are willing to give blood samples before treatment and if a rash develops.
- You have not been treated with mogamulizumab before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
This study looks at medical and disease details to find factors that can help predict how advanced mycosis fungoides or Sézary syndrome will behave. Your information may help doctors better estimate prognosis and plan care.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
This trial studies mogamulizumab (an antibody medicine) plus total skin electron beam therapy (whole-skin radiation) to treat cutaneous T-cell lymphoma. It may help by improving skin symptoms and controlling the lymphoma after prior treatments.
Hear when a new Recurrent Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.